Myrexis cancer news

Myrexis retained Stifel Nicolaus Weisel to evaluate strategic alternatives. Myrexis also suspended development of all its preclinical and clinical programs, including MPC-3100, a synthetic, non-geldanamycin inhibitor of heat shock protein 90 (Hsp90) in Phase I testing to treat cancer. The company said it intends to provide additional information "as appropriate." For its 2Q12 ending Dec. 31, Myrexis had $80.7 million in cash and a six-month operating loss of $16.3 million. ...